Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05025956 · ClinicalTrials.gov registry record · Phase 1
Senolytic Agent Improve the Benefit of Platelet-Rich Plasma and Losartan
A Phase 1 study of Femoroacetabular Impingement, sponsored by Steadman Philippon Research Institute.
- Active
- Registry status
- Phase 1
- Development phase
- 68
- Enrollment target
- 1
- Study location
NCT05025956: Active Phase 1 study of Femoroacetabular Impingement, sponsored by Steadman Philippon Research Institute.
NCT05025956 is a Phase 1 study of Femoroacetabular Impingement that is active but no longer recruiting, run by Steadman Philippon Research Institute. The registered enrollment target is 68 participants, below the 1,361-participant average among 8 other Femoroacetabular Impingement trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05025956, a Phase 1 study of Femoroacetabular Impingement, is active but no longer recruiting, sponsored by Steadman Philippon Research Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 68 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose is to explore the possible benefit of administration of Fisetin, (a senolytic agent) to improve the benefit of Platelet-Rich Plasma and losartan for treatment of femoroacetabular impingement and labral tear. We believe that giving Fisetin, a senolytic agent, will improve the benefit of PRP by eliminating senescent cells and senescence-associated secretory phenotype (SASP), known to exist in PRP. The main objectives of this study are to determine if pre- and post-operative administration of a senolytic agent will improve the beneficial effects of PRP when used in conjunction with surgical treatment of FAI and/or labral tear, to determine whether pre- and postoperative administration of Fisetin is associated with adverse events, and to determine if pre- and post-operative administration of Fisetin leads to a decrease in systemic senescence, serum SASP, and fibrotic markers. Patients suffering from femoroacetabular impingement and labral tear, who are planning to undergo hip arthroscopy combined with standard of care intra-operative PRP injection and post-operative losartan administration will be recruited from the clinical practice of the Principal Clinical Investigator or his designee at The Steadman Clinic (TSC).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Fisetin
Study Locations (1)
Colorado
- The Steadman Clinic - Vail
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2021-10-24 |
| Est. Completion | 2024-10-31 |
| Phase | Phase 1 |
What the registry record for NCT05025956 still lists
NCT05025956 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 68 participants, a relatively small participant target, below the 1,361-participant average among 8 other Femoroacetabular Impingement trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Femoroacetabular Impingement appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05025956 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT05025956 about?
NCT05025956 is a clinical study titled "Senolytic Agent Improve the Benefit of Platelet-Rich Plasma and Losartan". The purpose is to explore the possible benefit of administration of Fisetin, (a senolytic agent) to improve the benefit of Platelet-Rich Plasma and losartan for treatment of femoroacetabular impingement and labral tear. We believe that giving Fisetin, a senolytic agent, will improve the benefit of ...
What is the current status of trial NCT05025956?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2021-10-24. Estimated completion is 2024-10-31.
What conditions does trial NCT05025956 study?
This clinical trial studies the following conditions: Femoroacetabular Impingement.
What interventions are being tested in trial NCT05025956?
The interventions under investigation include: Placebo (DRUG), Fisetin (DRUG).
Who is sponsoring clinical trial NCT05025956?
This trial is sponsored by Steadman Philippon Research Institute, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05025956 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Femoroacetabular Impingement
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05025956's enrollment target sits among peer trials
68 7th of 8 higher than 2 of 8 other Femoroacetabular Impingement trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Femoroacetabular Impingement trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Feasibility Study of Cartilage Defect Repair
RECRUITING · NA
-
An Evaluation of Hip Preservation Outcomes
RECRUITING
-
Effect of PRP, PPP, & BMAC on Functional Outcomes Following Hip Arthroscopy for Acetabular Labral Pathologies
RECRUITING · Phase 3
-
Knotless Implants As an Alternative for Capsular Closure in Primary Hip Arthroscopy: a Prospective, Multi-Center Study
RECRUITING · Phase 4
-
Use of BMAC With Hip Arthroscopy Treatment of FAI and Labral Tear
RECRUITING
-
SCP Hip Outcomes Study
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02044497 · 68 participants · Phase 4
Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients
- NCT03779854 · 68 participants · Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
- NCT03821246 · 68 participants · Phase 2
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
- NCT04115514 · 68 participants · Phase 2
Treatment of ARDS With Instilled T3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI